Full Text of SB2038 100th General Assembly
SB2038sam001 100TH GENERAL ASSEMBLY | Sen. Chapin Rose Filed: 3/1/2017
| | 10000SB2038sam001 | | LRB100 11368 MJP 22277 a |
|
| 1 | | AMENDMENT TO SENATE BILL 2038
| 2 | | AMENDMENT NO. ______. Amend Senate Bill 2038 by replacing | 3 | | everything after the enacting clause with the following:
| 4 | | "Section 1. Short title. This Act may be cited as the | 5 | | Epinephrine Administration Act.
| 6 | | Section 5. Definitions. As used in this Act: | 7 | | "Authorized entity" means any entity or organization, | 8 | | other than a school covered under Section 22-30 of the School | 9 | | Code, in connection with or at which allergens capable of | 10 | | causing anaphylaxis may be present, including, but not limited | 11 | | to, independent contractors who provide student transportation | 12 | | to schools, recreation camps, colleges and universities, day | 13 | | care facilities, youth sports leagues, amusement parks, | 14 | | restaurants, sports arenas, and places of employment. The | 15 | | Department shall, by rule, determine what constitutes a day | 16 | | care facility under this definition. |
| | | 10000SB2038sam001 | - 2 - | LRB100 11368 MJP 22277 a |
|
| 1 | | "Department" means the Department of Public Health. | 2 | | "Epinephrine glass vial, ampule, or pre-filled syringe" | 3 | | means a glass vial of epinephrine, ampule of epinephrine, or | 4 | | pre-filled syringe of epinephrine used for the administration | 5 | | of a pre-measured dose of epinephrine into the human body. | 6 | | "Health care practitioner" means a physician licensed to | 7 | | practice medicine in all its branches under the Medical | 8 | | Practice Act of 1987, a physician assistant under the Physician | 9 | | Assistant Practice Act of 1987 with prescriptive authority, or | 10 | | an advanced practice nurse with prescribing authority under | 11 | | Article 65 of the Nurse Practice Act. | 12 | | "Pharmacist" has the meaning given to that term under | 13 | | subsection (k-5) of Section 3 of the Pharmacy Practice Act. | 14 | | "Undesignated epinephrine glass vial, ampule, or | 15 | | pre-filled syringe" means an epinephrine glass vial, ampule, or | 16 | | pre-filled syringe prescribed in the name of an authorized | 17 | | entity.
| 18 | | Section 10. Prescription to authorized entity; use; | 19 | | training. | 20 | | (a) A health care practitioner may prescribe epinephrine | 21 | | glass vials, ampules, or pre-filled syringes in the name of an | 22 | | authorized entity for use in accordance with this Act, and | 23 | | pharmacists and health care practitioners may dispense | 24 | | epinephrine glass vials, ampules, or pre-filled syringes | 25 | | pursuant to a prescription issued in the name of an authorized |
| | | 10000SB2038sam001 | - 3 - | LRB100 11368 MJP 22277 a |
|
| 1 | | entity. Such prescriptions shall be valid for a period of 2 | 2 | | years. | 3 | | (b) An authorized entity may acquire and stock a supply of | 4 | | undesignated epinephrine glass vials, ampules, or pre-filled | 5 | | syringes pursuant to a prescription issued under subsection (a) | 6 | | of this Section. Such undesignated epinephrine glass vials, | 7 | | ampules, or pre-filled syringes shall be stored in a location | 8 | | readily accessible in an emergency and in accordance with the | 9 | | instructions for use of the epinephrine glass vials, ampules, | 10 | | or pre-filled syringes. The Department may establish any | 11 | | additional requirements an authorized entity must follow under | 12 | | this Act. | 13 | | (c) An employee or agent of an authorized entity or other | 14 | | individual who has completed training under subsection (d) of | 15 | | this Section may: | 16 | | (1) provide an epinephrine glass vial, ampule, or | 17 | | pre-filled syringe to any individual on the property of the | 18 | | authorized entity whom the employee, agent, or other | 19 | | individual believes in good faith is experiencing | 20 | | anaphylaxis, or to the parent, guardian, or caregiver of | 21 | | such individual, for immediate administration, regardless | 22 | | of whether the individual has a prescription for an | 23 | | epinephrine glass vial, ampule, or pre-filled syringe or | 24 | | has previously been diagnosed with an allergy; or | 25 | | (2) administer epinephrine from a glass vial, ampule, | 26 | | or pre-filled syringe to any individual on the property of |
| | | 10000SB2038sam001 | - 4 - | LRB100 11368 MJP 22277 a |
|
| 1 | | the authorized entity whom the employee, agent, or other | 2 | | individual believes in good faith is experiencing | 3 | | anaphylaxis, regardless of whether the individual has a | 4 | | prescription for an epinephrine glass vial, ampule, or | 5 | | pre-filled syringe or has previously been diagnosed with an | 6 | | allergy. | 7 | | (d) An employee, agent, or other individual authorized must | 8 | | complete an anaphylaxis training program before he or she is | 9 | | able to provide or administer epinephrine from a glass vial, | 10 | | ampule, or pre-filled syringe under this Section. Such training | 11 | | shall be valid for a period of 2 years and shall be conducted | 12 | | by a nationally recognized organization experienced in | 13 | | training laypersons in emergency health treatment. The | 14 | | Department shall include links to training providers' websites | 15 | | on its website. | 16 | | Training shall include, but is not limited to: | 17 | | (1) how to recognize signs and symptoms of an allergic | 18 | | reaction, including anaphylaxis; | 19 | | (2) how to administer epinephrine from a glass vial, | 20 | | ampule, or pre-filled syringe; and | 21 | | (3) a test demonstrating competency of the knowledge | 22 | | required to recognize anaphylaxis and administer | 23 | | epinephrine from a glass vial, ampule, or pre-filled | 24 | | syringe. | 25 | | Training may also include, but is not limited to: | 26 | | (A) a review of high-risk areas on the authorized |
| | | 10000SB2038sam001 | - 5 - | LRB100 11368 MJP 22277 a |
|
| 1 | | entity's property and its related facilities; | 2 | | (B) steps to take to prevent exposure to allergens; | 3 | | (C) emergency follow-up procedures; and | 4 | | (D) other criteria as determined in rules adopted | 5 | | pursuant to this Act. | 6 | | Training may be conducted either online or in person. The | 7 | | Department shall approve training programs and list permitted | 8 | | training programs on the Department's Internet website. | 9 | | Section 15. Costs. Whichever entity initiates the process | 10 | | of obtaining undesignated epinephrine glass vials, ampules, or | 11 | | pre-filled syringes and providing training to personnel for | 12 | | carrying and administering epinephrine from undesignated | 13 | | epinephrine glass vials, ampules, or pre-filled syringes shall | 14 | | pay for the costs of the undesignated epinephrine glass vials, | 15 | | ampules, or pre-filled syringes.
| 16 | | Section 20. Limitations. The use of an undesignated | 17 | | epinephrine glass vial, ampule, or pre-filled syringe in | 18 | | accordance with the requirements of this Act does not | 19 | | constitute the practice of medicine or any other profession | 20 | | that requires medical licensure. | 21 | | Nothing in this Act shall limit the amount of epinephrine | 22 | | glass vials, ampules, or pre-filled syringes that an authorized | 23 | | entity or individual may carry or maintain a supply of.
|
| | | 10000SB2038sam001 | - 6 - | LRB100 11368 MJP 22277 a |
|
| 1 | | Section 85. Rulemaking. The Department shall adopt any | 2 | | rules necessary to implement and administer this Act.
| 3 | | Section 90. The School Code is amended by changing Section | 4 | | 22-30 as follows:
| 5 | | (105 ILCS 5/22-30)
| 6 | | Sec. 22-30. Self-administration and self-carry of asthma | 7 | | medication and epinephrine injectors auto-injectors ; | 8 | | administration of undesignated epinephrine injectors | 9 | | auto-injectors ; administration of an opioid antagonist; asthma | 10 | | episode emergency response protocol.
| 11 | | (a) For the purpose of this Section only, the following | 12 | | terms shall have the meanings set forth below:
| 13 | | "Asthma action plan" means a written plan developed with a | 14 | | pupil's medical provider to help control the pupil's asthma. | 15 | | The goal of an asthma action plan is to reduce or prevent | 16 | | flare-ups and emergency department visits through day-to-day | 17 | | management and to serve as a student-specific document to be | 18 | | referenced in the event of an asthma episode. | 19 | | "Asthma episode emergency response protocol" means a | 20 | | procedure to provide assistance to a pupil experiencing | 21 | | symptoms of wheezing, coughing, shortness of breath, chest | 22 | | tightness, or breathing difficulty. | 23 | | "Asthma inhaler" means a quick reliever asthma inhaler. | 24 | | "Epinephrine auto-injector" means a single-use device used |
| | | 10000SB2038sam001 | - 7 - | LRB100 11368 MJP 22277 a |
|
| 1 | | for the automatic injection of a pre-measured dose of | 2 | | epinephrine into the human body.
| 3 | | "Epinephrine injector" includes a glass vial, | 4 | | auto-injector, ampule, or pre-filled syringe used for the | 5 | | administration of epinephrine. | 6 | | "Asthma medication" means a medicine, prescribed by (i) a | 7 | | physician
licensed to practice medicine in all its branches,
| 8 | | (ii) a licensed physician assistant with prescriptive | 9 | | authority , or (iii) a licensed advanced practice
nurse with | 10 | | prescriptive authority
for a pupil that pertains to the pupil's
| 11 | | asthma and that has an individual prescription label.
| 12 | | "Opioid antagonist" means a drug that binds to opioid | 13 | | receptors and blocks or inhibits the effect of opioids acting | 14 | | on those receptors, including, but not limited to, naloxone | 15 | | hydrochloride or any other similarly acting drug approved by | 16 | | the U.S. Food and Drug Administration. | 17 | | "School nurse" means a registered nurse working in a school | 18 | | with or without licensure endorsed in school nursing. | 19 | | "Self-administration" means a pupil's discretionary use of | 20 | | his or
her prescribed asthma medication or epinephrine injector | 21 | | auto-injector .
| 22 | | "Self-carry" means a pupil's ability to carry his or her | 23 | | prescribed asthma medication or epinephrine injector | 24 | | auto-injector . | 25 | | "Standing protocol" may be issued by (i) a physician | 26 | | licensed to practice medicine in all its branches, (ii) a |
| | | 10000SB2038sam001 | - 8 - | LRB100 11368 MJP 22277 a |
|
| 1 | | licensed physician assistant with prescriptive authority , or | 2 | | (iii) a licensed advanced practice nurse with prescriptive | 3 | | authority. | 4 | | "Trained personnel" means any school employee or volunteer | 5 | | personnel authorized in Sections 10-22.34, 10-22.34a, and | 6 | | 10-22.34b of this Code who has completed training under | 7 | | subsection (g) of this Section to recognize and respond to | 8 | | anaphylaxis. | 9 | | "Undesignated epinephrine injector auto-injector " means an | 10 | | epinephrine injector auto-injector prescribed in the name of a | 11 | | school district, public school, or nonpublic school. | 12 | | (b) A school, whether public or nonpublic, must permit the
| 13 | | self-administration and self-carry of asthma
medication by a | 14 | | pupil with asthma or the self-administration and self-carry of | 15 | | an epinephrine injector auto-injector by a pupil, provided | 16 | | that:
| 17 | | (1) the parents or
guardians of the pupil provide to | 18 | | the school (i) written
authorization from the parents or | 19 | | guardians for (A) the self-administration and self-carry | 20 | | of asthma medication or (B) the self-carry of asthma | 21 | | medication or (ii) for (A) the self-administration and | 22 | | self-carry of an epinephrine injector auto-injector or (B) | 23 | | the self-carry of an epinephrine injector auto-injector , | 24 | | written authorization from the pupil's physician, | 25 | | physician assistant, or advanced practice nurse; and
| 26 | | (2) the
parents or guardians of the pupil provide to |
| | | 10000SB2038sam001 | - 9 - | LRB100 11368 MJP 22277 a |
|
| 1 | | the school (i) the prescription label, which must contain | 2 | | the name of the asthma medication, the prescribed dosage, | 3 | | and the time at which or circumstances under which the | 4 | | asthma medication is to be administered, or (ii) for the | 5 | | self-administration or self-carry of an epinephrine | 6 | | injector auto-injector , a
written
statement from the | 7 | | pupil's physician, physician assistant, or advanced | 8 | | practice
nurse containing
the following information:
| 9 | | (A) the name and purpose of the epinephrine | 10 | | injector auto-injector ;
| 11 | | (B) the prescribed dosage; and
| 12 | | (C) the time or times at which or the special | 13 | | circumstances
under which the epinephrine injector | 14 | | auto-injector is to be administered.
| 15 | | The information provided shall be kept on file in the office of | 16 | | the school
nurse or,
in the absence of a school nurse, the | 17 | | school's administrator.
| 18 | | (b-5) A school district, public school, or nonpublic school | 19 | | may authorize the provision of a student-specific or | 20 | | undesignated epinephrine injector auto-injector to a student | 21 | | or any personnel authorized under a student's Individual Health | 22 | | Care Action Plan, Illinois Food Allergy Emergency Action Plan | 23 | | and Treatment Authorization Form, or plan pursuant to Section | 24 | | 504 of the federal Rehabilitation Act of 1973 to administer an | 25 | | epinephrine injector auto-injector to the student, that meets | 26 | | the student's prescription on file. |
| | | 10000SB2038sam001 | - 10 - | LRB100 11368 MJP 22277 a |
|
| 1 | | (b-10) The school district, public school, or nonpublic | 2 | | school may authorize a school nurse or trained personnel to do | 3 | | the following: (i) provide an undesignated epinephrine | 4 | | injector auto-injector to a student for self-administration | 5 | | only or any personnel authorized under a student's Individual | 6 | | Health Care Action Plan, Illinois Food Allergy Emergency Action | 7 | | Plan and Treatment Authorization Form, or plan pursuant to | 8 | | Section 504 of the federal Rehabilitation Act of 1973 to | 9 | | administer to the student, that meets the student's | 10 | | prescription on file; (ii) administer an undesignated | 11 | | epinephrine injector auto-injector that meets the prescription | 12 | | on file to any student who has an Individual Health Care Action | 13 | | Plan, Illinois Food Allergy Emergency Action Plan and Treatment | 14 | | Authorization Form, or plan pursuant to Section 504 of the | 15 | | federal Rehabilitation Act of 1973 that authorizes the use of | 16 | | an epinephrine injector auto-injector ; (iii) administer an | 17 | | undesignated epinephrine injector auto-injector to any person | 18 | | that the school nurse or trained personnel in good faith | 19 | | believes is having an anaphylactic reaction; and (iv) | 20 | | administer an opioid antagonist to any person that the school | 21 | | nurse or trained personnel in good faith believes is having an | 22 | | opioid overdose. | 23 | | (c) The school district, public school, or nonpublic school | 24 | | must inform the parents or
guardians of the
pupil, in writing, | 25 | | that the school district, public school, or nonpublic school | 26 | | and its
employees and
agents, including a physician, physician |
| | | 10000SB2038sam001 | - 11 - | LRB100 11368 MJP 22277 a |
|
| 1 | | assistant, or advanced practice nurse providing standing | 2 | | protocol or prescription for school epinephrine injectors | 3 | | auto-injectors ,
are to incur no liability or professional | 4 | | discipline, except for willful and wanton conduct, as a result
| 5 | | of any injury arising from the
administration of asthma | 6 | | medication, an epinephrine injector auto-injector , or an | 7 | | opioid antagonist regardless of whether authorization was | 8 | | given by the pupil's parents or guardians or by the pupil's | 9 | | physician, physician assistant, or advanced practice nurse. | 10 | | The parents or guardians
of the pupil must sign a statement | 11 | | acknowledging that the school district, public school,
or | 12 | | nonpublic school and its employees and agents are to incur no | 13 | | liability, except for willful and wanton
conduct, as a result | 14 | | of any injury arising
from the
administration of asthma | 15 | | medication, an epinephrine injector auto-injector , or an | 16 | | opioid antagonist regardless of whether authorization was | 17 | | given by the pupil's parents or guardians or by the pupil's | 18 | | physician, physician assistant, or advanced practice nurse and | 19 | | that the parents or
guardians must indemnify and hold harmless | 20 | | the school district, public school, or nonpublic
school and
its
| 21 | | employees and agents against any claims, except a claim based | 22 | | on willful and
wanton conduct, arising out of the
| 23 | | administration of asthma medication, an epinephrine injector | 24 | | auto-injector , or an opioid antagonist regardless of whether | 25 | | authorization was given by the pupil's parents or guardians or | 26 | | by the pupil's physician, physician assistant, or advanced |
| | | 10000SB2038sam001 | - 12 - | LRB100 11368 MJP 22277 a |
|
| 1 | | practice nurse. | 2 | | (c-5) When a school nurse or trained personnel administers | 3 | | an undesignated epinephrine injector auto-injector to a person | 4 | | whom the school nurse or trained personnel in good faith | 5 | | believes is having an anaphylactic reaction or administers an | 6 | | opioid antagonist to a person whom the school nurse or trained | 7 | | personnel in good faith believes is having an opioid overdose, | 8 | | notwithstanding the lack of notice to the parents or guardians | 9 | | of the pupil or the absence of the parents or guardians signed | 10 | | statement acknowledging no liability, except for willful and | 11 | | wanton conduct, the school district, public school, or | 12 | | nonpublic school and its employees and agents, and a physician, | 13 | | a physician assistant, or an advanced practice nurse providing | 14 | | standing protocol or prescription for undesignated epinephrine | 15 | | injectors auto-injectors , are to incur no liability or | 16 | | professional discipline, except for willful and wanton | 17 | | conduct, as a result of any injury arising from the use of an | 18 | | undesignated epinephrine injector auto-injector or the use of | 19 | | an opioid antagonist regardless of whether authorization was | 20 | | given by the pupil's parents or guardians or by the pupil's | 21 | | physician, physician assistant, or advanced practice nurse.
| 22 | | (d) The permission for self-administration and self-carry | 23 | | of asthma medication or the self-administration and self-carry | 24 | | of an epinephrine injector auto-injector is effective
for the | 25 | | school year for which it is granted and shall be renewed each
| 26 | | subsequent school year upon fulfillment of the requirements of |
| | | 10000SB2038sam001 | - 13 - | LRB100 11368 MJP 22277 a |
|
| 1 | | this
Section.
| 2 | | (e) Provided that the requirements of this Section are | 3 | | fulfilled, a
pupil with asthma may self-administer and | 4 | | self-carry his or her asthma medication or a pupil may | 5 | | self-administer and self-carry an epinephrine injector | 6 | | auto-injector (i) while in
school, (ii) while at a | 7 | | school-sponsored activity, (iii) while under the
supervision | 8 | | of
school personnel, or (iv) before or after normal school | 9 | | activities, such
as while in before-school or after-school care | 10 | | on school-operated
property or while being transported on a | 11 | | school bus.
| 12 | | (e-5) Provided that the requirements of this Section are | 13 | | fulfilled, a school nurse or trained personnel may administer | 14 | | an undesignated epinephrine injector auto-injector to any | 15 | | person whom the school nurse or trained personnel in good faith | 16 | | believes to be having an anaphylactic reaction (i) while in | 17 | | school, (ii) while at a school-sponsored activity, (iii) while | 18 | | under the supervision of school personnel, or (iv) before or | 19 | | after normal school activities, such
as while in before-school | 20 | | or after-school care on school-operated property or while being | 21 | | transported on a school bus. A school nurse or trained | 22 | | personnel may carry undesignated epinephrine injectors | 23 | | auto-injectors on his or her person while in school or at a | 24 | | school-sponsored activity. | 25 | | (e-10) Provided that the requirements of this Section are | 26 | | fulfilled, a school nurse or trained personnel may administer |
| | | 10000SB2038sam001 | - 14 - | LRB100 11368 MJP 22277 a |
|
| 1 | | an opioid antagonist to any person whom the school nurse or | 2 | | trained personnel in good faith believes to be having an opioid | 3 | | overdose (i) while in school, (ii) while at a school-sponsored | 4 | | activity, (iii) while under the supervision of school | 5 | | personnel, or (iv) before or after normal school activities, | 6 | | such as while in before-school or after-school care on | 7 | | school-operated property. A school nurse or trained personnel | 8 | | may carry an opioid antagonist on their person while in school | 9 | | or at a school-sponsored activity. | 10 | | (f) The school district, public school, or nonpublic school | 11 | | may maintain a supply of undesignated epinephrine injectors | 12 | | auto-injectors in any secure location that is accessible | 13 | | before, during, and after school where an allergic person is | 14 | | most at risk, including, but not limited to, classrooms and | 15 | | lunchrooms. A physician, a physician assistant who has been | 16 | | delegated prescriptive authority in accordance with Section | 17 | | 7.5 of the Physician Assistant Practice Act of 1987, or an | 18 | | advanced practice nurse who has been delegated prescriptive | 19 | | authority in accordance with Section 65-40 of the Nurse | 20 | | Practice Act may prescribe undesignated epinephrine injectors | 21 | | auto-injectors in the name of the school district, public | 22 | | school, or nonpublic school to be maintained for use when | 23 | | necessary. Any supply of epinephrine injectors auto-injectors | 24 | | shall be maintained in accordance with the manufacturer's | 25 | | instructions. | 26 | | The school district, public school, or nonpublic school may |
| | | 10000SB2038sam001 | - 15 - | LRB100 11368 MJP 22277 a |
|
| 1 | | maintain a supply of an opioid antagonist in any secure | 2 | | location where an individual may have an opioid overdose. A | 3 | | health care professional who has been delegated prescriptive | 4 | | authority for opioid antagonists in accordance with Section | 5 | | 5-23 of the Alcoholism and Other Drug Abuse and Dependency Act | 6 | | may prescribe opioid antagonists in the name of the school | 7 | | district, public school, or nonpublic school, to be maintained | 8 | | for use when necessary. Any supply of opioid antagonists shall | 9 | | be maintained in accordance with the manufacturer's | 10 | | instructions. | 11 | | (f-3) Whichever entity initiates the process of obtaining | 12 | | undesignated epinephrine injectors auto-injectors and | 13 | | providing training to personnel for carrying and administering | 14 | | undesignated epinephrine injectors auto-injectors shall pay | 15 | | for the costs of the undesignated epinephrine injectors | 16 | | auto-injectors . | 17 | | (f-5) Upon any administration of an epinephrine injector | 18 | | auto-injector , a school district, public school, or nonpublic | 19 | | school must immediately activate the EMS system and notify the | 20 | | student's parent, guardian, or emergency contact, if known. | 21 | | Upon any administration of an opioid antagonist, a school | 22 | | district, public school, or nonpublic school must immediately | 23 | | activate the EMS system and notify the student's parent, | 24 | | guardian, or emergency contact, if known. | 25 | | (f-10) Within 24 hours of the administration of an | 26 | | undesignated epinephrine injector auto-injector , a school |
| | | 10000SB2038sam001 | - 16 - | LRB100 11368 MJP 22277 a |
|
| 1 | | district, public school, or nonpublic school must notify the | 2 | | physician, physician assistant, or advanced practice nurse who | 3 | | provided the standing protocol or prescription for the | 4 | | undesignated epinephrine injector auto-injector of its use. | 5 | | Within 24 hours after the administration of an opioid | 6 | | antagonist, a school district, public school, or nonpublic | 7 | | school must notify the health care professional who provided | 8 | | the prescription for the opioid antagonist of its use. | 9 | | (g) Prior to the administration of an undesignated | 10 | | epinephrine injector auto-injector , trained personnel must | 11 | | submit to their school's administration proof of completion of | 12 | | a training curriculum to recognize and respond to anaphylaxis | 13 | | that meets the requirements of subsection (h) of this Section. | 14 | | Training must be completed annually. their The school district, | 15 | | public school, or nonpublic school must maintain records | 16 | | related to the training curriculum and trained personnel. | 17 | | Prior to the administration of an opioid antagonist, | 18 | | trained personnel must submit to their school's administration | 19 | | proof of completion of a training curriculum to recognize and | 20 | | respond to an opioid overdose, which curriculum must meet the | 21 | | requirements of subsection (h-5) of this Section. Training must | 22 | | be completed annually. Trained personnel must also submit to | 23 | | the school's administration proof of cardiopulmonary | 24 | | resuscitation and automated external defibrillator | 25 | | certification. The school district, public school, or | 26 | | nonpublic school must maintain records relating to the training |
| | | 10000SB2038sam001 | - 17 - | LRB100 11368 MJP 22277 a |
|
| 1 | | curriculum and the trained personnel. | 2 | | (h) A training curriculum to recognize and respond to | 3 | | anaphylaxis, including the administration of an undesignated | 4 | | epinephrine injector auto-injector , may be conducted online or | 5 | | in person. | 6 | | Training shall include, but is not limited to: | 7 | | (1) how to recognize signs and symptoms of an allergic | 8 | | reaction, including anaphylaxis; | 9 | | (2) how to administer an epinephrine injector | 10 | | auto-injector ; and | 11 | | (3) a test demonstrating competency of the knowledge | 12 | | required to recognize anaphylaxis and administer an | 13 | | epinephrine injector auto-injector . | 14 | | Training may also include, but is not limited to: | 15 | | (A) a review of high-risk areas within a school and its | 16 | | related facilities; | 17 | | (B) steps to take to prevent exposure to allergens; | 18 | | (C) emergency follow-up procedures; | 19 | | (D) how to respond to a student with a known allergy, | 20 | | as well as a student with a previously unknown allergy; and | 21 | | (E) other criteria as determined in rules adopted | 22 | | pursuant to this Section. | 23 | | In consultation with statewide professional organizations | 24 | | representing physicians licensed to practice medicine in all of | 25 | | its branches, registered nurses, and school nurses, the State | 26 | | Board of Education shall make available resource materials |
| | | 10000SB2038sam001 | - 18 - | LRB100 11368 MJP 22277 a |
|
| 1 | | consistent with criteria in this subsection (h) for educating | 2 | | trained personnel to recognize and respond to anaphylaxis. The | 3 | | State Board may take into consideration the curriculum on this | 4 | | subject developed by other states, as well as any other | 5 | | curricular materials suggested by medical experts and other | 6 | | groups that work on life-threatening allergy issues. The State | 7 | | Board is not required to create new resource materials. The | 8 | | State Board shall make these resource materials available on | 9 | | its Internet website. | 10 | | (h-5) A training curriculum to recognize and respond to an | 11 | | opioid overdose, including the administration of an opioid | 12 | | antagonist, may be conducted online or in person. The training | 13 | | must comply with any training requirements under Section 5-23 | 14 | | of the Alcoholism and Other Drug Abuse and Dependency Act and | 15 | | the corresponding rules. It must include, but is not limited | 16 | | to: | 17 | | (1) how to recognize symptoms of an opioid overdose; | 18 | | (2) information on drug overdose prevention and | 19 | | recognition; | 20 | | (3) how to perform rescue breathing and resuscitation; | 21 | | (4) how to respond to an emergency involving an opioid | 22 | | overdose; | 23 | | (5) opioid antagonist dosage and administration; | 24 | | (6) the importance of calling 911; | 25 | | (7) care for the overdose victim after administration | 26 | | of the overdose antagonist; |
| | | 10000SB2038sam001 | - 19 - | LRB100 11368 MJP 22277 a |
|
| 1 | | (8) a test demonstrating competency of the knowledge | 2 | | required to recognize an opioid overdose and administer a | 3 | | dose of an opioid antagonist; and | 4 | | (9) other criteria as determined in rules adopted | 5 | | pursuant to this Section. | 6 | | (i) Within 3 days after the administration of an | 7 | | undesignated epinephrine injector auto-injector by a school | 8 | | nurse, trained personnel, or a student at a school or | 9 | | school-sponsored activity, the school must report to the State | 10 | | Board of Education in a form and manner prescribed by the State | 11 | | Board the following information: | 12 | | (1) age and type of person receiving epinephrine | 13 | | (student, staff, visitor); | 14 | | (2) any previously known diagnosis of a severe allergy; | 15 | | (3) trigger that precipitated allergic episode; | 16 | | (4) location where symptoms developed; | 17 | | (5) number of doses administered; | 18 | | (6) type of person administering epinephrine (school | 19 | | nurse, trained personnel, student); and | 20 | | (7) any other information required by the State Board. | 21 | | If a school district, public school, or nonpublic school | 22 | | maintains or has an independent contractor providing | 23 | | transportation to students who maintains a supply of | 24 | | undesignated epinephrine injectors auto-injectors , then the | 25 | | school district, public school, or nonpublic school must report | 26 | | that information to the State Board of Education upon adoption |
| | | 10000SB2038sam001 | - 20 - | LRB100 11368 MJP 22277 a |
|
| 1 | | or change of the policy of the school district, public school, | 2 | | nonpublic school, or independent contractor, in a manner as | 3 | | prescribed by the State Board. The report must include the | 4 | | number of undesignated epinephrine injectors auto-injectors in | 5 | | supply. | 6 | | (i-5) Within 3 days after the administration of an opioid | 7 | | antagonist by a school nurse or trained personnel, the school | 8 | | must report to the State Board of Education , in a form and | 9 | | manner prescribed by the State Board, the following | 10 | | information: | 11 | | (1) the age and type of person receiving the opioid | 12 | | antagonist (student, staff, or visitor); | 13 | | (2) the location where symptoms developed; | 14 | | (3) the type of person administering the opioid | 15 | | antagonist (school nurse or trained personnel); and | 16 | | (4) any other information required by the State Board. | 17 | | (j) By October 1, 2015 and every year thereafter, the State | 18 | | Board of Education shall submit a report to the General | 19 | | Assembly identifying the frequency and circumstances of | 20 | | epinephrine administration during the preceding academic year. | 21 | | Beginning with the 2017 report, the report shall also contain | 22 | | information on which school districts, public schools, and | 23 | | nonpublic schools maintain or have independent contractors | 24 | | providing transportation to students who maintain a supply of | 25 | | undesignated epinephrine injectors auto-injectors . This report | 26 | | shall be published on the State Board's Internet website on the |
| | | 10000SB2038sam001 | - 21 - | LRB100 11368 MJP 22277 a |
|
| 1 | | date the report is delivered to the General Assembly. | 2 | | (j-5) Annually, each school district, public school, | 3 | | charter school, or nonpublic school shall request an asthma | 4 | | action plan from the parents or guardians of a pupil with | 5 | | asthma. If provided, the asthma action plan must be kept on | 6 | | file in the office of the school nurse or, in the absence of a | 7 | | school nurse, the school administrator. Copies of the asthma | 8 | | action plan may be distributed to appropriate school staff who | 9 | | interact with the pupil on a regular basis, and, if applicable, | 10 | | may be attached to the pupil's federal Section 504 plan or | 11 | | individualized education program plan. | 12 | | (j-10) To assist schools with emergency response | 13 | | procedures for asthma, the State Board of Education, in | 14 | | consultation with statewide professional organizations with | 15 | | expertise in asthma management and a statewide organization | 16 | | representing school administrators, shall develop a model | 17 | | asthma episode emergency response protocol before September 1, | 18 | | 2016. Each school district, charter school, and nonpublic | 19 | | school shall adopt an asthma episode emergency response | 20 | | protocol before January 1, 2017 that includes all of the | 21 | | components of the State Board's model protocol. | 22 | | (j-15) Every 2 years, school personnel who work with pupils | 23 | | shall complete an in-person or online training program on the | 24 | | management of asthma, the prevention of asthma symptoms, and | 25 | | emergency response in the school setting. In consultation with | 26 | | statewide professional organizations with expertise in asthma |
| | | 10000SB2038sam001 | - 22 - | LRB100 11368 MJP 22277 a |
|
| 1 | | management, the State Board of Education shall make available | 2 | | resource materials for educating school personnel about asthma | 3 | | and emergency response in the school setting. | 4 | | (j-20) On or before October 1, 2016 and every year | 5 | | thereafter, the State Board of Education shall submit a report | 6 | | to the General Assembly and the Department of Public Health | 7 | | identifying the frequency and circumstances of opioid | 8 | | antagonist administration during the preceding academic year. | 9 | | This report shall be published on the State Board's Internet | 10 | | website on the date the report is delivered to the General | 11 | | Assembly. | 12 | | (k) The State Board of Education may adopt rules necessary | 13 | | to implement this Section. | 14 | | (l) Nothing in this Section shall limit the amount of | 15 | | epinephrine injectors auto-injectors that any type of school or | 16 | | student may carry or maintain a supply of. | 17 | | (Source: P.A. 98-795, eff. 8-1-14; 99-173, eff. 7-29-15; | 18 | | 99-480, eff. 9-9-15; 99-642, eff. 7-28-16; 99-711, eff. 1-1-17; | 19 | | 99-843, eff. 8-19-16; revised 9-8-16.)".
|
|